Avadel Pharmaceuticals Beheer

Hoe is Greg Divis's beloning veranderd ten opzichte van Avadel Pharmaceuticals's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$106m
Mar 31 2024	n/a	n/a	-US$157m
Dec 31 2023	US$985k	US$600k	-US$160m
Sep 30 2023	n/a	n/a	-US$159m
Jun 30 2023	n/a	n/a	-US$143m
Mar 31 2023	n/a	n/a	-US$142m
Dec 31 2022	US$754k	US$561k	-US$137m
Sep 30 2022	n/a	n/a	-US$132m
Jun 30 2022	n/a	n/a	-US$134m
Mar 31 2022	n/a	n/a	-US$90m
Dec 31 2021	US$3m	US$545k	-US$77m
Sep 30 2021	n/a	n/a	-US$66m
Jun 30 2021	n/a	n/a	-US$56m
Mar 31 2021	n/a	n/a	-US$6m
Dec 31 2020	US$3m	US$520k	US$7m
Sep 30 2020	n/a	n/a	US$16m
Jun 30 2020	n/a	n/a	US$18m
Mar 31 2020	n/a	n/a	-US$21m
Dec 31 2019	US$1m	US$472k	-US$33m
Sep 30 2019	n/a	n/a	-US$94m
Jun 30 2019	n/a	n/a	-US$101m
Mar 31 2019	n/a	n/a	-US$96m
Dec 31 2018	US$685k	US$417k	-US$95m
Sep 30 2018	n/a	n/a	-US$40m
Jun 30 2018	n/a	n/a	-US$2m
Mar 31 2018	n/a	n/a	US$30m
Dec 31 2017	US$1m	US$375k	US$68m

Compensatie versus markt: De totale vergoeding ($USD 985.20K ) Greg } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 5.54M ).

Compensatie versus inkomsten: De vergoeding van Greg is gestegen terwijl het bedrijf verliesgevend is.

CEO

Greg Divis (57 yo)

5.8yrs

Tenure

US$985,200

Compensatie

Mr. Gregory J. Divis Jr., also known as Greg, has been Director of Avadel Pharmaceuticals plc since June 3, 2019 and has been its Chief Executive Officer since January 2019. Mr. Divis served as an Interim...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Gregory Divis	CEO & Director	5.8yrs	US$985.20k	geen gegevens
Thomas McHugh	Senior VP	4.9yrs	US$663.14k	0.084% $ 1.2m
Richard Kim	Chief Commercial Officer	3.8yrs	US$770.95k	0% $ 0
Jerad Seurer	General Counsel & Company Secretary	4.2yrs	geen gegevens	0.0091% $ 134.6k
Gregory Davis	VP of Corporate and Business Development	9.3yrs	geen gegevens	0.17% $ 2.4m
Mark Elrod	Vice President of Sales	8.3yrs	geen gegevens	geen gegevens
Angie Woods	Vice President of People & Culture	3.5yrs	geen gegevens	geen gegevens
Jordan Dubow	Consultant	5.6yrs	US$982.54k	geen gegevens
Jason Vaughn	Senior Vice President of Technical Operations	4.9yrs	geen gegevens	geen gegevens
Jennifer Gudeman	Senior Vice President of Medical & Clinical Affairs	no data	geen gegevens	geen gegevens

4.9yrs

Gemiddelde duur

56yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van AVDL wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.9 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Gregory Divis	CEO & Director	5.4yrs	US$985.20k	geen gegevens
Jean-Marie Lehn	Member of Scientific Advisory Board	19.8yrs	geen gegevens	geen gegevens
Mark McCamish	Independent Director	4.9yrs	US$449.84k	0.070% $ 1.0m
Naseem Amin	Independent Director	less than a year	geen gegevens	geen gegevens
Peter Thornton	Independent Director	7.4yrs	US$459.84k	0.086% $ 1.3m
Christian Trepo	Member of Scientific Advisory Board	19.8yrs	geen gegevens	geen gegevens
Patrick Couvreur	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Eric Ende	Independent Director	5.9yrs	US$452.34k	0.17% $ 2.6m
Catherine Bréchignac	Chairman of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Geoffrey Glass	Independent Non-Executive Chairman of the Board	6.3yrs	US$482.34k	0.13% $ 1.9m
Linda Palczuk	Independent Director	6.3yrs	US$452.34k	0.054% $ 801.7k

6.3yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van AVDL wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.3 jaar).

Avadel Pharmaceuticals Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Avadel Pharmaceuticals plc, Annual General Meeting, Jul 30, 2024

Avadel Pharmaceuticals plc, Annual General Meeting, Jul 30, 2024

Avadel Pharmaceuticals plc Appoints Naseem Amin to Its Board of Directors

Avadel Pharmaceuticals plc Appoints Naseem Amin to Its Board of Directors

Independent Director recently sold US$1.1m worth of stock

Independent Director notifies of intention to sell stock

Recent updates

Avadel Pharmaceuticals plc to Report Q3, 2024 Results on Nov 12, 2024

Avadel Pharmaceuticals and nference, Inc. Publish Real-World Data on Narcolepsy in Sleep Advances

Avadel Pharmaceuticals Announces FDA Approval of LUMRYZ (sodium oxybate) Extended-Release Oral Suspension (CIII) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Patients 7 Years of Age and Older with Narcolepsy

Avadel Pharmaceuticals plc's (NASDAQ:AVDL) P/S Still Appears To Be Reasonable

Health Check: How Prudently Does Avadel Pharmaceuticals (NASDAQ:AVDL) Use Debt?

Avadel Pharmaceuticals plc Announces Publication of Restore Data Highlighting Challenges with Twice-Nightly Oxybates and Strong Patient Preference for Once-Nightly LUMRYZ Dosing (sodium Oxybate) Extended-Release Oral Suspension (CIII)

Avadel Pharmaceuticals: The Oxybate War With Jazz Waxes On

Avadel Pharmaceuticals plc Announces Publication in Clinical Therapeutics of Data Highlighting Weight Loss in People with Narcolepsy Treated with LUMRYZ™ (sodium oxybate) Extended-Release Oral Suspension

Avadel Pharmaceuticals plc to Report Q2, 2024 Results on Aug 08, 2024

Avadel Pharmaceuticals plc Announces First Patient Dosed in Phase 3 REVITALYZ Trial of LUMRYZ (sodium oxybate) Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

Avadel Pharmaceuticals plc, Annual General Meeting, Jul 30, 2024

Avadel Pharmaceuticals plc, Annual General Meeting, Jul 30, 2024

Avadel Pharmaceuticals: Inflection Point Ahead

Avadel Pharmaceuticals plc Appoints Naseem Amin to Its Board of Directors

Avadel Pharmaceuticals Shares New LUMRYZ (sodium Oxybate) for Extended-Release Oral Suspension (CIII) Data at Sleep 2024

Avadel Pharmaceuticals plc Appoints Naseem Amin to Its Board of Directors

Avadel Pharmaceuticals plc has completed a Follow-on Equity Offering.

Avadel Pharmaceuticals plc has filed a Follow-on Equity Offering in the amount of $100 million.

Avadel Pharmaceuticals plc to Report Q1, 2024 Results on May 08, 2024

New major risk - Share price stability

Avadel Pharmaceuticals: A Deep Dive Into Lumryz's Once-Nightly Revolution

Price target increased by 8.0% to US$22.90

Avadel Pharmaceuticals: Robust Launch Of Lumryz And Eased Litigation Overhang

Avadel Pharmaceuticals: Strong Launch Of Lumryz With A Legal Risk Backdrop

Is Avadel Pharmaceuticals (NASDAQ:AVDL) Weighed On By Its Debt Load?

Avadel May Continue To Outperform With Positive Launch Momentum

Avadel Pharmaceuticals plc to Report Fiscal Year 2023 Results on Feb 29, 2024

Independent Director recently sold US$1.1m worth of stock

Independent Director notifies of intention to sell stock

Consensus revenue estimates increase by 18%, EPS downgraded

Avadel Pharmaceuticals Announces Data Supporting Clinical Profile for Lumryz (Sodium Oxybate) for Extended-Release Oral Suspension (Ciii) At World Sleep 2023

Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt Sensibly?

New minor risk - Insider selling

Consensus EPS estimates fall by 54%, revenue upgraded

Key Executive recently bought US$188k worth of stock

Avadel Pharmaceuticals plc to Report Q2, 2023 Results on Aug 09, 2023

Are Investors Undervaluing Avadel Pharmaceuticals plc (NASDAQ:AVDL) By 49%?

Price target increased by 7.1% to US$19.33

Consensus EPS estimates upgraded to US$1.28 loss

Avadel Pharmaceuticals plc Announces Publication of Study Data in Advances in Therapy Highlighting Need for Once-At-Bedtime Oxybate Dosing for Narcolepsy

Price target increased by 9.8% to US$18.06

Avadel Pharmaceuticals plc Announces U.S. Commercial Launch of LUMRYZ for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Adults Living with Narcolepsy

Avadel Pharmaceuticals plc Announces Data Supporting Clinical Profile for LUMRYZ™ at SLEEP 2023

Independent Director recently bought US$181k worth of stock

Consensus revenue estimates increase by 17%

Is There An Opportunity With Avadel Pharmaceuticals plc's (NASDAQ:AVDL) 45% Undervaluation?

Price target increased by 20% to US$15.85

Consensus revenue estimates fall by 15%

Consensus revenue estimates increase by 15%, EPS downgraded

Avadel Pharmaceuticals plc Announces Publication of Real-World Data Describing Risk of Accidental Dosing Errors with Immediate-Release Twice-Nightly Oxybate

Insufficient new directors

Price target increased to US$12.25

Independent Director recently bought US$156k worth of stock

Avadel Pharmaceuticals Presents New Real-World Data Describing Demographic Characteristics and Comorbidities of Patients with Narcolepsy at ANA 2022

Avadel Pharmaceuticals filed for 500M mixed shelf offering

Price target increased to US$10.95

Avadel Pharmaceuticals Q2 2022 Earnings Preview

Price target increased to US$10.10

Avadel Pharmaceuticals plc Announces Tentative Approval of LUMRYZ Extended-Release Oral Suspension

Avadel Pharmaceuticals (NASDAQ:AVDL) Is Carrying A Fair Bit Of Debt

Avadel Pharmaceuticals Provides Corporate Update

Avadel rises 18% as it expects tentative approval for sleep disorder drug; expects final approval by June 2023

Avadel: Further Delay, But Some Light At The End Of The Tunnel

Senior VP & CFO recently bought US$107k worth of stock

Price target decreased to US$11.30

Consensus revenue estimates fall by 15%

Avadel Pharmaceuticals plc to Report Q1, 2022 Results on May 09, 2022

Avadel Pharmaceuticals plc, Annual General Meeting, Aug 04, 2022

Consensus revenue estimates fall by 16%